Transdermal delivery peptides and method of use thereof
View Patent ↗Transdermal delivery peptides for the treatment of skin diseases and/or facilitation or enhancement of transdermal delivery of pharmaceutically active agents are provided. Compositions comprising the transdermal delivery peptides and methods of therapeutic use, including the improvement of transdermal delivery of drugs or other pharmaceutically active agents, are also disclosed. Nucleic acids, expression vectors, and methods of their use, which encode the transdermal delivery peptides are disclosed. Methods are also provided for in vivo phage display for identifying further peptides with enhanced transdermal delivery capability.
1. An isolated peptide having an amino acid sequence as set forth in SEQ ID NO:1 (TD-2), SEQ ID NO:2 (TD-1), or SEQ ID NO:4 (TD-10).
2. The peptide of claim 1 , wherein said peptide has an amino acid sequence of SEQ ID NO:1 (TD-2).
3. The peptide of claim 1 , wherein said peptide has an amino acid sequence of SEQ ID NO:2 (TD-1).
4. The peptide of claim 1 , wherein said peptide has an amino acid sequence of SEQ ID NO:4 (TD-10).
5. The peptide of claim 1 , wherein said peptide enhances transdermal delivery of a pharmaceutically active agent.
6. The peptide of claim 5 , wherein said pharmaceutically active agent is selected from the group consisting of insulin, growth hormone, apomorphine, and PT-141.
7. The peptide of claim 5 , wherein said pharmaceutically active agent is insulin.
8. A composition for transdermal delivery comprising a peptide having an amino acid sequence as set forth in SEQ ID NO:1 (TD-2), SEQ ID NO:2 (TD-1), or SEQ ID NO:4 (TD-10).
9. The composition of claim 8 , wherein said peptide comprises an amino acid sequence of SEQ ID NO:1 (TD-2).
10. The composition of claim 8 , wherein said peptide has an amino acid sequence of SEQ ID NO:2 (TD-1).
11. The composition of claim 8 , wherein said peptide has an amino acid sequence of SEQ ID NO:4 (TD-10).
12. The composition of claim 8 , further comprising a pharmaceutically active agent.
13. The composition of claim 12 , wherein said pharmaceutically active agent is selected from the group consisting of insulin, growth hormone, apomorphine, and PT-141.
14. The composition of claim 12 , wherein said pharmaceutically active agent is insulin.
15. A method of transdermal delivery comprising administering to the skin of a subject in need thereof a therapeutically effective amount of a composition comprising a pharmaceutically acceptable carrier, a pharmaceutically active agent, and a peptide having an amino acid sequence as set forth in SEQ ID NO:I (TD-2), SEQ ID NO:2 (TD-1), or SEQ ID NO:4 (TD-10).